Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies

References

• Yeo W, Chan PKS, Zong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemother-apy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299–307.
   PubMed Web of Science ®Google Scholar
• Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Int Med J 2007; 35: 705–712.
   Web of Science ®Google Scholar
• Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699–712.
   PubMed Web of Science ®Google Scholar
• Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182–188.
   PubMed Web of Science ®Google Scholar
• Yagcl M, Acar K, Sucak GT, Aki Z, Bozdayi G, Haznedar R. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBsAg carriers with hematologic malig-nancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 2006; 47: 1608–1612.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Ho WM et al. Lamivudinee for the preventionof hepatitis B virus resctivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Gun Oncol 2004; 22: 927–943.
   Web of Science ®Google Scholar
• Zhong S, Yeo W, Schroder C et al. High hepatitis B virus DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004; 11: 55–59.
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Au WY et al. Hepatitis B reactivation afterwithdrawal of pre-emptive lamivudinee in patients with haemato-logical malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597–1603.
   PubMed Web of Science ®Google Scholar
• Lau GKK, Leung YH, Fong DY et al. High hepatitis B virus (HBV) viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen under-going autologous hematopoietic stem cell transplantation. Blood 2002; 99: 2324–2330.
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsiung CA, Su II et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepathology 2003; 37: 1320–1328.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Mele A, Spada E et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554–557.
   PubMed Web of Science ®Google Scholar
• Takai S, Tsurumi H, Ando K et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005; 74: 158–165.
   PubMed Web of Science ®Google Scholar
• Kim JH, Bang YJ, Park BJ et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res 2002; 93: 471–477.
   PubMedGoogle Scholar
• Kuniyoshi M, Nakamuta M, Sakai H et al. Prevalence of hepatitisB or C virus infections in patients with non-Hodgkin's lymphoma. Gastroenterol Hepatol 2001; 16: 215–219.
   Web of Science ®Google Scholar
• Cucuianu A, Patiu M, Duma M et al. Hepatitis B and C virus infection in Romanian non-Hodgkin's lymphoma patients. Br J Haematol 1999; 107: 353–356.
   PubMed Web of Science ®Google Scholar
• Rossi D, Sala L, Minisini R et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 604–611.
   PubMed Web of Science ®Google Scholar
• Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24\(Suppl. 1): 3–10.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Wong ML, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890–1897.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605–611.
   PubMed Web of Science ®Google Scholar
• He YF, Li YH, Wang FH et al. The effectiveness of lamivudine inpreventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008; 87: 481–485.
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudinee therapy for hepatitis B patients under-going chemotherapy. Gastroenterology 2003; 125: 1742–1749.
   PubMed Web of Science ®Google Scholar
• Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malig-nancies treated with chemotherapy-a prospective case series. Am J Hematol 2005; 80: 197–203.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudi-nee pophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006; 24: 1003–1016.
   PubMed Web of Science ®Google Scholar
• Li YH, He YF, Jiang WQ et al. Lamivudinee prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320–1325.
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamuvidine for chemotherapy-associated hepatitis B reactivation reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009: 94: 998–1005.
   PubMed Web of Science ®Google Scholar
• Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamuvidine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepatitis 2008; 15: 89–102.
   PubMed Web of Science ®Google Scholar
• Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58–62.
   PubMed Web of Science ®Google Scholar
• Ozguroglu M, Bilici A, Turna H, Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004; 21: 67–72.
   PubMed Web of Science ®Google Scholar
• Ling R, Mutimer D, Ahmed N et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudinee. Hepatology 1996; 24: 711–713.
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudinee for chronic hepatitis B. Asia hepatitis lamivudinee study group. N Engl J Med 1998; 339: 61–68.
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Chien RN et al. Four years of lamivudinee treatment in Chinese patents with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276–1282.
   PubMed Web of Science ®Google Scholar